Cardiopulmonary effects of low-dose arginine vasopressin in ovine acute lung injury

Critical Care Medicine

Volumn 39, Issue 2, 2011, Pages 357-363

  Westphal, Martin ^a,c   Rehberg, Sebastian ^a,c   Maybauer, Marc O ^a   Maybauer, Dirk M ^a   Enkhbaatar, Perenlei ^a   Westphal Varghese, Beena B ^a   Schmalstieg, Frank C ^a   Morita, Naoki ^a   Cox, Robert A ^a   Traber, Lillian D ^a   Hawkins, Hal ^a   Whorton, Elbert ^b   Traber, Daniel L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

acute respiratory distress syndrome; arginine vasopressin; burn; nitrosative stress; smoke inhalation injury

Indexed keywords

3 NITROTYROSINE; ARGIPRESSIN;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; BRONCHUS OBSTRUCTION; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY FUNCTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUID BALANCE; FLUID RESUSCITATION; HEART LEFT VENTRICLE; HEART STROKE VOLUME; HEMODYNAMICS; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG EDEMA; LUNG GAS EXCHANGE; NITROSATIVE STRESS; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; PULMONARY SHUNT; SHEEP; SMALL AIRWAY DISEASE;

EID: 79251537684     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181feb802     Document Type: Article

References (35)

1. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
2. Luckner G, Dü nser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33:2659-2666
3. Torgersen C, Dü nser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010; 36:57-65
4. Tayama E, Ueda T, Shojima T, et al: Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg 2007; 6:715-719
5. Vincent JL, Su F: Physiology and pathophysiology of the vasopressinergic system. Best Pract Res Clin Anaesthesiol 2008; 22: 243-252
6. Holmes CL, Landry DW, Granton JT: Science Review: Vasopressin and the cardiovascular system part 2-Clinical physiology. Crit Care 2004; 8:15-23
7. Kusano E, Tian S, Umino T, et al: Arginine vasopressin inhibits interleukin-1 betastimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens 1997; 15:627-632
8. Umino T, Kusano E, Muto S, et al: AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 1999; 276(3 Pt 2): F433-F441
9. Yamamoto K, Ikeda U, Okada K, et al: Arginine vasopressin inhibits nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Hypertens Res 1997; 20: 209-216
10. Rehberg S, Maybauer MO, Maybauer DM, et al: The role of nitric oxide and reactive nitrogen species in experimental ARDS. Front Biosci 2010; S2:18-29
11. Enkhbaatar P, Murakami K, Shimoda K, et al: The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. Am J Respir Crit Care Med 2003; 167: 1021-1026 (Pubitemid 36408169)
12. Lange M, Connelly R, Traber DL, et al: Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury. Crit Care Med 2009; 37:223-229
13. Sharma S, Smith A, Kumar S, et al: Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: Role of asymmetric dimethylarginine. Vascul Pharmacol 2010; 52:182-190
14. Soejima K, Traber LD, Schmalstieg FC, et al: Role of nitric oxide in vascular permeability after combined burns and smoke inhalation injury. Am J Respir Crit Care Med 2001; 163:745-752 (Pubitemid 32230839)
15. Westphal M, Enkhbaatar P, Schmalstieg FC, et al: Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep. Crit Care Med 2008; 36:1196-1204
16. Westphal M, Cox RA, Traber LD, et al: Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction. Crit Care Med 2006; 34:1428-1436
17. Enkhbaatar P, Connelly R, Wang J, et al: Inhibition of neuronal nitric oxide synthase in ovine model of acute lung injury. Crit Care Med 2009; 37:208-214
18. Baxter CR, Shires T: Physiological response to crystalloid resuscitation of severe burns. Ann N Y Acad Sci 1968; 150:874-894
19. Pearce ML, Yamashita J, Beazell J: Measurement of pulmonary edema. Circ Res 1965; 16:482-488
20. Cox RA, Burke AS, Soejima K, et al: Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol 2003; 29:295-302
21. Moreau R, Barrière E, Tazi KA, et al: Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology 2002; 36: 1070-1078
22. Kurtovic J, Boyle M, Bihari D, et al: Nitricoxide- lowering effect of terlipressin in decompensated cirrhosis: Comparison to the molecular adsorbent recirculating system and correlation with clinical status. Eur J Gastroenterol Hepatol 2004; 16:1335-1338
23. Enkhbaatar P, Murakami K, Traber LD, et al: The inhibition of inducible nitric oxide synthase in ovine sepsis model. Shock 2006; 25:522-527
24. Enkhbaatar P, Traber DL: Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clin Sci (Lond) 2004; 107:137-143
25. Cox RA, Jacob S, Oliveras G, et al: Pulmonary expression of nitric oxide synthase isoforms in sheep with smoke inhalation and burn injury. Exp Lung Res 2009; 35:104-118
26. Bak Z, Sjöberg F, Eriksson O, et al: Cardiac dysfunction after burns. Burns 2008; 34: 603-609
27. Soejima K, Schmalstieg FC, Sakurai H, et al: Pathophysiological analysis of combined burn and smoke inhalation injuries in sheep. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1233-L1241
28. Muller-Werdan U, Buerke M, Ebelt H, et al: Septic cardiomyopathy-A not yet discovered cardiomyopathy? Exp Clin Cardiol 2006; 11:226-236
29. Russ RD, Resta TC, Walker BR: Pulmonary vasodilatory response to neurohypophyseal peptides in the rat. J Appl Physiol 1992; 73: 473-478
30. Ertmer C, Rehberg S, Westphal M: Vasopressin analogues in the treatment of shock states: Potential pitfalls. Best Pract Res Clin Anaesthesiol 2008; 22:393-406
31. Holm C, Tegeler J, Mayr M, et al: Effect of crystalloid resuscitation and inhalation injury on extravascular lung water: Clinical implications. Chest 2002; 121:1956-1962
32. Dai NT, Chen TM, Cheng TY, et al: The comparison of early fluid therapy in extensive flame burns between inhalation and noninhalation injuries. Burns 1998; 24:671-675
33. Rehberg S, Enkhbaatar P, Yamamoto Y, et al: Selective V1a agonism reduces vascular leakage and cardiopulmonary dysfunction in MRSA sepsis. Crit Care 2010; 14(Suppl 1): P397
34. Rehberg S, Ertmer C, Traber DL, et al: Selective vs. unselective V1-receptor agonism in ovine septic shock. Am J Respir Crit Care Med 2009; 179:A1152
35. Rehberg S, Ertmer C, Kö hler G, et al: Role of arginine vasopressin and terlipressin as firstline vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009; 35: 1286-1296